US site closures as Takeda restructures vaccines business
This article was originally published in Scrip
A fundamental restructuring of Takeda Pharmaceutical's vaccines operations will see the closure of three sites in the US as it consolidates operations in this market in the Boston area as part of a revised global network for the unit.
You may also be interested in...
Plus deals involving WuXi AppTec/OXGENE, Oscotec/Beatica, ReViral/LianBio, Wugen/HCW Biologics, Starton/Haisco, Shanghai Junshi/AstraZeneca, HitGen/Uppthera, Bridge/LegoChem, Macrogen/Lifex, BeiGene/Boston Immune
Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.
This time we touch on Pfizer’s R&D plans, real-world evidence for coronavirus vaccines, a new approval in lung cancer, challenges for Galapagos, and Takeda's pipeline story.